1. Home
  2. BBIO vs STVN Comparison

BBIO vs STVN Comparison

Compare BBIO & STVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BBIO
  • STVN
  • Stock Information
  • Founded
  • BBIO 2015
  • STVN 1949
  • Country
  • BBIO United States
  • STVN Italy
  • Employees
  • BBIO N/A
  • STVN N/A
  • Industry
  • BBIO Biotechnology: Pharmaceutical Preparations
  • STVN Containers/Packaging
  • Sector
  • BBIO Health Care
  • STVN Consumer Discretionary
  • Exchange
  • BBIO Nasdaq
  • STVN Nasdaq
  • Market Cap
  • BBIO 8.0B
  • STVN 6.6B
  • IPO Year
  • BBIO 2019
  • STVN 2021
  • Fundamental
  • Price
  • BBIO $45.12
  • STVN $24.49
  • Analyst Decision
  • BBIO Strong Buy
  • STVN Buy
  • Analyst Count
  • BBIO 14
  • STVN 6
  • Target Price
  • BBIO $58.85
  • STVN $25.08
  • AVG Volume (30 Days)
  • BBIO 3.3M
  • STVN 349.3K
  • Earning Date
  • BBIO 07-31-2025
  • STVN 08-05-2025
  • Dividend Yield
  • BBIO N/A
  • STVN 0.25%
  • EPS Growth
  • BBIO N/A
  • STVN N/A
  • EPS
  • BBIO N/A
  • STVN 0.50
  • Revenue
  • BBIO $127,415,000.00
  • STVN $1,215,562,040.00
  • Revenue This Year
  • BBIO $102.05
  • STVN $8.69
  • Revenue Next Year
  • BBIO $54.69
  • STVN $10.67
  • P/E Ratio
  • BBIO N/A
  • STVN $49.48
  • Revenue Growth
  • BBIO N/A
  • STVN 3.81
  • 52 Week Low
  • BBIO $21.72
  • STVN $16.85
  • 52 Week High
  • BBIO $45.48
  • STVN $25.88
  • Technical
  • Relative Strength Index (RSI)
  • BBIO 77.53
  • STVN 60.72
  • Support Level
  • BBIO $39.65
  • STVN $22.51
  • Resistance Level
  • BBIO $45.18
  • STVN $24.80
  • Average True Range (ATR)
  • BBIO 1.49
  • STVN 1.18
  • MACD
  • BBIO 0.54
  • STVN 0.10
  • Stochastic Oscillator
  • BBIO 99.13
  • STVN 77.15

About BBIO BridgeBio Pharma Inc.

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

About STVN Stevanato Group S.p.A.

Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, the company derives majority revenue from Europe, Middle East and Africa.

Share on Social Networks: